GlassScriptPhysician profile
Stephen Matthew Perkey
NPI 1356658488
$28,713.06
in general payments reported to CMS, 2019-2025
20 companies · $18.28 in 2025
The $18.28 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,053 · 2022: $1,298 · 2023: $26K · 2024: $224 · 2025: $18.28.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $23K · Travel and Lodging: $2,293 · Food and Beverage: $1,556 · Education: $7.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $22,505.00 |
| Travel and Lodging | $2,292.99 |
| Food and Beverage | $1,556.23 |
| Education | $7.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $16,012.79 | 2021-2024 | Lybalvi, Aristada, Vivitrol |
| Abbvie INC. | $10,699.65 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $433.90 | 2021-2025 | Invega Trinza, Invega Sustenna |
| Sunovion Pharmaceuticals INC. | $257.27 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $249.55 | 2021-2024 | Rexulti, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $238.77 | 2022-2023 | |
| Teva Pharmaceuticals USA, INC. | $168.29 | 2022-2024 | Austedo, Austedo Xr, Uzedy |
| Lundbeck LLC | $142.58 | 2021-2023 | Rexulti |
| Supernus Pharmaceuticals, INC. | $136.55 | 2021-2024 | Qelbree, Qelbree |
| Vanda Pharmaceuticals INC. | $84.65 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $66.84 | 2021-2022 | |
| Uswm, LLC | $52.68 | 2023 | Zimhi, Lucemyra |
| Pfizer INC. | $47.40 | 2021-2022 | |
| Indivior INC. | $29.01 | 2022 | |
| Axsome Therapeutics, INC. | $22.28 | 2023 | Auvelity |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $16.72 | 2021 | |
| Idorsia Pharmaceuticals US INC | $15.77 | 2023 | Quviviq |
| Astrazeneca Pharmaceuticals LP | $13.15 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $12.69 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.52 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Perkey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.